PDCD1 and central nervous system cancer: We have developed a novel therapeutic strategy by “dressing” oncolytic viruses with anti-PD-1 antibodies and alendronate (PD-1/Al@OV) to prevent premature clearance of the oncolytic viruses and enhance T cell function, thereby improving immunotherapy outcomes against glioma.